key: cord-0708816-bh050xv0
authors: Chen, Yi‐An; Huang, Hsin‐Yin; Wu, Shu‐Hao; Huang, Ting‐Chun
title: Thrombosis of the palmar digital vein after Oxford‐AstraZeneca COVID‐19 vaccination
date: 2021-09-02
journal: Int J Dermatol
DOI: 10.1111/ijd.15897
sha: 1e4f870920b39de87f4a081f3db93b5a7a1abe01
doc_id: 708816
cord_uid: bh050xv0

nan

Dear Editor,

In the era of COVID-19, the distribution and administration of approved vaccines is a fundamental step to control the pandemic.

Although studies of the vaccination show safety and effectiveness, concerns over possible side effects affect people's willingness to accept the immunization and the extent of coverage. Oxford-AstraZeneca vaccine, a chimpanzee adenoviral vector (ChAdOx1) encoding the SARS-CoV-2 spike protein DNA, is available worldwide but notable for the rare associated thrombotic events. 1 hood. Until recently, urticarial rash associated with COVID-19 has been described in especially adult patients, but the number reported in children is very few. As a result of three metaanalyses published, in the pediatric population, symptoms such as runny nose and nasal congestion are observed at a rate of 7-20%, while skin rash has been reported as less than 1%. [3] [4] [5] Here, we want to present an infant who presented with acute urticarial rash with angioedema who was diagnosed with COVID-19, which has been reported much less frequently. A 12-month-old healthy girl presented to the outside hospital 3 days prior because of itchy skin rash (urticaria) and eye edema (angioedema) that started on the trunk and spread to the whole body ( Figs. 1 and 2) . She was admitted to our hospital when her skin rash continued despite oral antihistaminic treatments and intramuscular methylprednisolone treatment given at an external center for 3 days. In the physical examination of the patient who was hospitalized with the prediagnosis of acute urticaria, resistant to therapy, there was no additional positive physical examination finding, except for erythematous and edematous rashes on the skin that lasted for 3 days. In her history, it was learned that there was a fever of 38°C for 1 day in the beginning of the rash but had disappeared with an antipyretic therapy. It was learned that there was no diarrhea, fatigue, anorexia, cough, or respiratory distress. The patient had no contact with a known COVID-19 patient. There was no previous drug or food allergy or urticaria in her medical history.

There was no history of allergy or atopy in the medical history of the family. When the laboratory examinations of the patient were performed, the COVID-19 PCR result was positive, and the patient was then followed up in the COVID-19 inpatient service. D-dimer and C-reactive protein elevation was present ( 

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis of the palmar digital veins: a report of 6 cases and a review of the literature

Palmar digital vein thrombosis in a patient with COVID-19

Leukocytoclastic vasculitis flare following the COVID-19 vaccine

Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca Covid-19 vaccination

Written consent was obtained from the patient for the publication of images and case details in all formats. All authors had full access to all the data in the study and accept the responsibility to submit it for publication.